Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer

Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer

Background: Radiotherapy is one of the primary therapies for localized prostatic carcinoma. Therefore, there is an emerging need to sensitize prostatic cancer cells to chemotherapy/radiotherapy. Modified citrus pectin (MCP) is an effective inhibitor of galectin-3 (Gal-3), which is correlated with tu...

Full description

Bibliographic Details
Main Authors: Sefora Conti MSc, Akiva Vexler MD, PhD, Lior Hagoel MSc, Lital Kalich-Philosoph PhD, Benjamin W. Corn MD, Nir Honig, Natan Shtraus MSc, Yaron Meir BSc, Ilan Ron MD, PhD, Isaac Eliaz MD, Shahar Lev-Ari PhD
Format: Article
Language:English
Published: SAGE Publishing 2018-12-01
Series:Integrative Cancer Therapies
Online Access:https://doi.org/10.1177/1534735418790382

Internet

https://doi.org/10.1177/1534735418790382

Similar Items